Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.58 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.55 |
| ▸ | HTR3B | O95264 | 1/20 | 0.55 |
| ▸ | HTR3A | P46098 | 1/20 | 0.55 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.55 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.50 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.46 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.46 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.45 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760593 | 1.00 | CHRNA7 (0.58) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL14390376 | 1.00 | CHRNA7 (0.58) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL1723210 | 0.98 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL1723211 | 0.98 | CHRNA7 (0.56) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL16759127 | 0.90 | CHRNA7 (0.55) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL1912949 | 0.90 | CHRNA7 (0.61) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL27771638 | 0.89 | CHRNA7 (0.54) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL6621806 | 0.89 | CHRNA7 (0.54) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| Hydrochloric Acid SCHEMBL9312509 | 0.88 | MEN1 (0.62) | CHRNA7HTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29135438 | 0.86 | CHRNA7 (0.60) | CHRNA7HTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3941922-A1 | INHIBITORS OF RAF KINASES | Kinnate Biopharma Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-102656141-B | Micromolecular compound of simulation hemopoieticgrowth factor and uses thereof | LIGAND PHARMACEUTICALS INC. (US) | 2016-04-06 | — | — | CN | disclosed |
| CN-103282034-A | Use of hematopoietic growth factor mimetics | LIGAND PHARM INC | 2013-09-04 | — | — | CN | disclosed |
| EP-2463282-B1 | 4-Benzylamino-1-carboxyacyl-piperidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis | NOVARTIS AG (CH) | 2013-08-07 | — | — | EP | disclosed |
| US-20130190502-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-07-25 | — | — | US | disclosed |
| US-8440682-B2 | 4-benzylamino-1-carboxylacyl-piperidine derivatives as CETP inhibitors | NOVARTIS AG (CH) | 2013-05-14 | — | — | US | disclosed |
| US-8431709-B2 | Acylation reaction of hydroxyl group | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2013-04-30 | — | — | US | disclosed |
| US-8420641-B2 | Method of inhibiting CETP activity with 4-benzylamino-1-carboxylacyl-piperidine derivatives | NOVARTIS AG (CH) | 2013-04-16 | — | — | US | disclosed |
| US-20120264773-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2012-10-18 | — | — | US | disclosed |
| CN-102656141-A | Hematopoietic growth factor mimetic small molecule compounds and their uses | LIGAND PHARM INC | 2012-09-05 | — | — | CN | disclosed |
| EP-2207775-B1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2012-03-21 | — | — | EP | disclosed |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2010-09-30 | — | — | US | disclosed |
| EP-2207775-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | Novartis Ag (CH) | 2010-07-21 | — | — | EP | disclosed |
| EP-2196451-A1 | ACYLATION REACTION OF HYDROXYL GROUP | Takasago International Corporation (JP) | 2010-06-16 | — | — | EP | disclosed |
| WO-2009059943-A1 | 4-BENZYLAMINO-1-CARBOXYACYL-PIPERIDINE DERIVATIVES AS CETP INHIBITORS USEFUL FOR THE TREATMENT OF DISEASES SUCH AS HYPERLIPIDEMIA OR ARTERIOSCLEROSIS | NOVARTIS AG (CH) | 2009-05-14 | — | — | WO | disclosed |
| US-20090118287-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-05-07 | — | — | US | disclosed |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | CARDIOME PHARMA CORP. (CA) | 2007-05-03 | — | — | US | disclosed |
| EP-0865445-A1 | 3-AMINOETHYL-N-AMIDINO-2,5-DIHYDROPYRROLE DERIVATIVES HAVING ARGININE MIMETIC PROPERTIES | Roche Diagnostics GmbH (DE) | 1998-09-23 | — | — | EP | disclosed |
| WO-1997021725-A1 | 3-AMINOETHYL-N-AMIDINO-2,5-DIHYDROPYRROLE DERIVATIVES HAVING ARGININE MIMETIC PROPERTIES | BOEHRINGER MANNHEIM GMBH (DE) | 1997-06-19 | — | — | WO | disclosed |
| EP-0182213-B1 | CARBAPENEM COMPOUNDS AND PRODUCTION THEREOF | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1990-09-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190502-A1 | ACYLATION REACTION OF HYDROXYL GROUP | ADH5, ADH1A, ACADM | CHRNA7 3184/4885HTR3E 3082/4885HTR3B 2612/4885 |
| US-20120264773-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CHRNA7 3118/4885HTR3E 1589/4885HTR3B 1412/4885 |
| US-20090118287-A1 | ORGANIC COMPOUNDS | CETP, NPC1, CES1 | CHRNA7 3118/4885HTR3E 1589/4885HTR3B 1412/4885 |
| US-20100249422-A1 | ACYLATION REACTION OF HYDROXYL GROUP | ADH5, ADH1A, ACADM | CHRNA7 3184/4885HTR3E 3082/4885HTR3B 2612/4885 |
| US-20070099983-A1 | Aminocyclohexyl ether compounds and uses thereof | KCNH2, KCNC1, KCNH3 | CHRNA7 464/4885HTR3E 757/4885HTR3B 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.